C-35-X

C-35-X is a preclinical-stage allogeneic, universal chimeric antigen receptor natural killer (CAR-NK) cell therapy being developed by Chongqing Precision Biotech. As an allogeneic or off-the-shelf product, it is engineered to be administered to multiple patients without the requirement for autologous cell sourcing. The therapy utilizes the company's proprietary CAR-NK platform to enhance the innate cytotoxic capabilities of natural killer cells against tumor targets. While the specific antigen targeted by C-35-X has not been publicly disclosed, the program is aimed at treating malignant tumors by leveraging the specificity of chimeric antigen receptors combined with the safety profile of NK cells.